Rein Therapeutics, Inc. (NASDAQ:RNTX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$50M · US$1 a share · Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC Dealers: Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC (lead) Use of proceeds: Fully fund the Phase 2 trial of LTI-03 in IPF through completion, plus working capital and general corporate purposes | Apr 30, 2026 |
| Pre-paid advances repayable in common stock Announced: up to US$6M Buyers: Yorkville Advisors Global, LP (affiliate) (up to $6 million in pre-paid advances, initial $1 million funded at signing) Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes | Jul 30, 2025 |
| Common stock under standby equity purchase agreement Announced: up to US$15M Buyers: Yorkville Advisors Global, LP (affiliate) (up to $15 million of common stock over 36 months at Rein's option) Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes | Jul 30, 2025 |